Risk of hepatocellular carcinoma after hepatitis C virus cure

被引:0
|
作者
Maria Alejandra Luna-Cuadros [1 ]
Hao-Wei Chen [1 ]
Hira Hanif [1 ]
Mukarram Jamat Ali [1 ]
Muzammil Muhammad Khan [1 ]
Daryl Tan-Yeung Lau [1 ]
机构
[1] Liver Center, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School
关键词
D O I
暂无
中图分类号
R512.63 []; R735.7 [肝肿瘤];
学科分类号
100214 ; 100401 ;
摘要
Hepatitis C virus(HCV) is a significant cause of hepatocellular carcinoma(HCC).The direct-acting antivirals marked a new era of HCV therapy and are associated with greater than 95% cure rate.Successful treatment of chronic hepatitis C greatly reduces the risk of HCC.A proportion of patients, especially those with pre-existing cirrhosis, remain at risk for HCC despite sustained virologic response(SVR).Diabetes mellitus, hepatic steatosis, alcohol consumption and lack of fibrosis regression are associated with risks of HCC after HCV cure.Noninvasive modalities such as aspartate aminotransferase to platelet ratio index and fibrosis-4 index and transient elastography have been used to monitor hepatic fibrosis.More recently, various fibrosis scores have been combined with clinical parameters and other novel biomarkers to predict risks of HCC for patients who achieved SVR.These models still need to be validated and standardized prior to applying to routine clinical care.
引用
收藏
页码:96 / 107
页数:12
相关论文
共 50 条
  • [1] Risk of Hepatocellular Carcinoma After Cure of Hepatitis C Virus
    Ponzetto, Antonio
    Figura, Natale
    [J]. GASTROENTEROLOGY, 2018, 154 (05) : 1549 - 1549
  • [2] Risk of hepatocellular carcinoma after hepatitis C virus cure
    Luna-Cuadros, Maria Alejandra
    Chen, Hao-Wei
    Hanif, Hira
    Ali, Mukarram Jamat
    Khan, Muzammil Muhammad
    Lau, Daryl Tan-Yeung
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (01) : 96 - 107
  • [3] Hepatocellular Carcinoma Risk After Hepatitis C Cure
    Oloruntoba, Omobonike O.
    Muir, Andrew J.
    [J]. CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES, 2018, 10 (02) : 330 - 336
  • [4] Hepatocellular Carcinoma Risk After Hepatitis C Cure
    Omobonike O. Oloruntoba
    Andrew J. Muir
    [J]. Current Treatment Options in Infectious Diseases, 2018, 10 (2) : 330 - 336
  • [5] Persisting Risk of Hepatocellular Carcinoma After Hepatitis C Virus Cure Monitored by a Liver Transcriptome Signature
    Ono, Atsushi
    Goossens, Nicolas
    Finn, Richard S.
    Schmidt, Warren N.
    Thung, Swan N.
    Im, Gene Y.
    Hoshida, Yujin
    [J]. HEPATOLOGY, 2017, 66 (04) : 1344 - 1346
  • [6] Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
    Mezzacappa, Catherine
    Kim, Nicole J.
    Vutien, Philip
    Kaplan, David E.
    Ioannou, George N.
    Taddei, Tamar H.
    [J]. JAMA NETWORK OPEN, 2024, 7 (07)
  • [7] Persistence of Hepatocellular Carcinoma Risk after Hepatitis C Virus Eradication
    Han, Sojung
    Park, Jun Yong
    [J]. KOREAN JOURNAL OF GASTROENTEROLOGY, 2020, 75 (05): : 308 - 310
  • [8] FIB-4 score and hepatocellular carcinoma risk after hepatitis C virus cure: time to revise surveillance?
    Saviano, Antonio
    Tripon, Simona
    Baumert, Thomas F.
    [J]. HEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (05) : 661 - 664
  • [9] PREDICTIVE SCORES FOR HEPATOCELLULAR CARCINOMA OCCURRENCE AFTER HEPATITIS C VIRUS CURE WITH DIRECT ANTIVIRALS
    Muzica, Cristina
    Stanciu, C.
    Huiban, Laura
    Girleanu, Irina
    Petrea, Oana
    Cadar, Ramona
    Zenovia, S.
    Cuciureanu, T.
    Nastasa, R.
    Stratina, Ermina
    Stafie, R.
    Rotaru, A.
    Minea, H.
    Singeap, Ana-Maria
    Sfarti, C.
    Chiriac, S.
    Cojocariu, Camelia
    Trifan, Anca
    [J]. MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2023, 127 (03): : 365 - 372
  • [10] Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma
    Baumert, Thomas F.
    Hoshida, Yujin
    [J]. VIRUSES-BASEL, 2019, 11 (05):